GlassScriptPhysician profile
Lori Josey Barker
NPI 1922547744
$9,600.20
in general payments reported to CMS, 2019-2025
48 companies · $1,255 in 2025
The $1,255 reported for 2025 was more than what 89% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,650 · 2022: $2,105 · 2023: $1,899 · 2024: $1,692 · 2025: $1,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,845.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,438.36 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $870.10 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $762.89 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $701.68 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $604.89 | 2021-2025 | |
| Glaxosmithkline, LLC. | $571.33 | 2021-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Otsuka America Pharmaceutical, INC. | $433.84 | 2022-2025 | Rexulti |
| Pfizer INC. | $399.25 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.87 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $275.83 | 2021-2025 | |
| Mylan Specialty L.P. | $228.71 | 2021-2024 | Yupelri |
| Astellas Pharma US INC | $223.01 | 2021-2024 | Myrbetriq, Veozah |
| Biohaven Pharmaceuticals, INC. | $195.17 | 2021 | |
| Xeris Pharmaceuticals, INC. | $180.78 | 2021-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $173.85 | 2021-2023 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.